Figure 3 .

C3 deficient mice are protected from aPL antibody induced pregnancy complications. C3+/+ mice (B6/Sv129F1) were treated with aPL-IgG (10 mg ip) (aPL) or normal human IgG (Cntrl IgG) on days 8 and 12 of pregnancy. Half of the mice in each group received Crry-Ig (3 mg ip) every other day from days 8–12 and half received control murine IgG (mIgG). C3-/- mice were treated with either aPL-IgG or normal human IgG. Pregnancy outcomes were assessed as described in the legend for fig 2. There were 10–14 mice in each experimental group. (A) Analysis of the four groups of C3+/+ mice shows that treatment with aPL-IgG caused an increase in frequency of fetal resorptions in this strain (*aPL + mIgG v Cntrl IgG + mIgG p<0.01), while C3-/- were protected from aPL induced pregnancy loss (aPL v Cntrl IgG p=NS). In the C3+/+ mice, Crry-Ig prevented aPL induced fetal resorption (*aPL + mIgG v aPL + Crry-Ig p<0.01). (B) Similarly, aPL treatment caused a decrease in fetal weight in C3+/+ mice (*aPL + mIgG v Cntrl IgG + mIgG p<0.01), which was absent in C3-/- mice, and this was ameliorated by Crry-Ig (*aPL + mIgG v aPL + Crry-Ig p<0.01). Reproduced from the J Exp Med 2001;195:216 by copyright permission of The Rockefeller Press.